Allergy/Asthma News

Tralokinumab improved epidermal pathology, reduced inflammation and changed significant skin biomarkers in patients with atopic dermatitis, according to a study published in The European Journal of Allergy and Clinical Immunology.

SAN ANTONIO — Personalized treatment strategies can help providers overcome barriers to biologic care for patients with asthma, Lukena Karkhanis, MD, said at the 16th Annual Allergy, Asthma & Immunology CME Conference.

As your paycheck grows, so does your discretionary spending and saving. While it is easy to spend, it is not always clear where to invest your next dollar intended for future spending.

The FDA has approved neffy epinephrine nasal spray for emergency treatment of Type 1 allergic reactions, including anaphylaxis, in pediatric and adult individuals weighing at least 66 pounds.

Dupilumab showed continuous efficacy and safety in the long-term treatment of atopic dermatitis, according to a study.

Women traditionally spend significantly more time than men completing housework such as cooking and cleaning, putting them at risk for higher exposures to harmful agents that are known to cause respiratory and allergic issues, experts said.

SAN ANTONIO — With a little patience, physicians can challenge and delabel NSAID hypersensitivity in the office, David A. Khan, MD, said during the 16th Annual Allergy, Asthma & Immunology CME Conference.

Delgocitinib cream has shown efficacy in the treatment of hand eczema in two phase 3 trials.

The FDA approved an expanded label for Xembify, a 20% subcutaneous immunoglobulin used to treat primary immunodeficiencies produced by Grifols, according to a company press release.

SAN ANTONIO — Preparation is key to successful oral food challenges, said Maria Crain, APRN, CPNP-PC, AE-C, pediatric nurse practitioner, University of Texas Southwestern Medical Center Food Allergy Center.